Juliane Walz
University Hospital Tuebingen
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Juliane Walz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05069051 · Belimumab in Patients with Chronic Lymphocytic LeukemiaUniversity Hospital Tuebingen · active not recruiting · Chronic Lymphoid Leukemia in Relapse · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:33 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial.Lancet · 2016571 citationsRCR 27.2
- 214 citationsRCR 13.1
- Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.JAMA Pediatr · 2018114 citationsRCR 6.7
- 105 citationsRCR 3.0
- 75 citationsRCR 2.5
- Noninvasively determined muscle oxygen saturation is an early indicator of central hypovolemia in humans.J Appl Physiol (1985) · 200864 citationsRCR 2.8
- Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation.Neurosci Lett · 201162 citationsRCR 2.2
- Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.Ann Oncol · 200851 citationsRCR 1.1
- Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.Front Immunol · 202131 citationsRCR 1.5
- Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.Nat Commun · 202329 citationsRCR 2.1